Get the Stockscreener App
0.1721
8.24%
0.0131
Klotho Neurosciences Inc stock is traded at $0.1721, with a volume of 114.39K.
It is up +8.24% in the last 24 hours and down -33.83% over the past month.
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.
See More
Previous Close:
$0.159
Open:
$0.1526
24h Volume:
114.39K
Relative Volume:
0.39
Market Cap:
$4.47M
Revenue:
-
Net Income/Loss:
$-4.23M
P/E Ratio:
-0.8164
EPS:
-0.2108
Net Cash Flow:
-
1W Performance:
+1.24%
1M Performance:
-33.83%
6M Performance:
-64.15%
1Y Performance:
+0.00%
1-Day Range:
$0.1526
$0.182
1-Week Range:
$0.144
$0.182
52-Week Range:
$0.1135
$0.9473
Klotho Neurosciences Inc Stock (KLTO) Company Profile
Name
Klotho Neurosciences Inc
Sector
Industry
Phone
646-916-5315
Address
1115 BROADWAY, NEW YORK
Compare KLTO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KLTO
Klotho Neurosciences Inc
|
0.1721 | 4.47M | 0 | -4.23M | 0 | -0.2108 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Klotho Neurosciences Inc Stock (KLTO) Latest News
Form PRE 14AOther preliminary proxy statements - ADVFN
Klotho Neurosciences faces Nasdaq delisting risk By Investing.com - Investing.com South Africa
Klotho Neurosciences faces Nasdaq delisting risk - Investing.com
Klotho Neurosciences receives Nasdaq compliance extension - Investing.com Australia
Klotho Neurosciences receives Nasdaq compliance extension By Investing.com - Investing.com Canada
KLTO stock touches 52-week low at $0.19 amid sharp annual decline - Investing.com India
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Klotho Neurosciences to Acquire SkyBell Tech Subsidiary By Investing.com - Investing.com South Africa
Klotho Neurosciences to Acquire SkyBell Tech Subsidiary - Investing.com
Klotho Neurosciences, Inc. SEC 10-K Report - TradingView
Klotho Neurosciences Inc. (KLTO) reports earnings - qz.com
KLTO stock touches 52-week low at $0.25 amid sharp annual decline - Investing.com Canada
Exelixis (NASDAQ:EXEL) & Klotho Neurosciences (NASDAQ:KLTO) Financial Analysis - Defense World
Pre-market Movers: BTAI, VRPX, DCGO, NBY... - RTTNews
Klotho Neurosciences faces Nasdaq delisting By Investing.com - Investing.com Australia
Klotho Neurosciences faces Nasdaq delisting - Investing.com India
Citigroup Begins Coverage on Candel Therapeutics (NASDAQ:CADL) - Defense World
Why Apple Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Critical Comparison: Klotho Neurosciences (NASDAQ:KLTO) versus IN8bio (NASDAQ:INAB) - Defense World
Klotho Neurosciences, Inc. announced that it expects to receive $2 million in funding -January 22, 2025 - Marketscreener.com
Klotho Neurosciences secures $2M in convertible notes and warrants By Investing.com - Investing.com Canada
Klotho Neurosciences secures $2M in convertible notes and warrants - Investing.com India
Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco - The Manila Times
Pre-market Movers: ONCO, COEP, NUVB, SPRC... - RTTNews
Head to Head Contrast: Klotho Neurosciences (NASDAQ:KLTO) & ImmunityBio (NASDAQ:IBRX) - Defense World
Klotho Neurosciences, Inc. announced that it has received $1 million in funding from ACM Projektentwicklung GmbH - Marketscreener.com
Klotho Neurosciences secures $1.2 million convertible note By Investing.com - Investing.com Canada
Klotho Neurosciences secures $1.2 million convertible note - Investing.com India
Klotho Neurosciences, Inc. Appoints Dr. Merit Cudkowicz to Scientific Advisory Board - Marketscreener.com
Dr. Merit Cudkowicz, Renowned ALS Expert at Massachusetts General Hospital (MGH), Joins Klotho Neurosciences' Scientific Advisory Board - The Manila Times
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
Dr. Merit Cudkowicz, Renowned ALS Expert at Massachusetts - GlobeNewswire
Dr. Merit Cudkowicz, Renowned ALS Expert at Massachusetts General Hospital (MGH), Joins Klotho Neurosciences’ Scientific Advisory Board - Yahoo Finance
Former Merck USA President Joins Klotho Neurosciences' Board of Directors - The Manila Times
Former Merck USA President Joins Klotho Neurosciences’ Board of Directors - GlobeNewswire
Klotho Neurosciences Taps Former Merck US President Who Led $12B Portfolio to Board of Directors - StockTitan
Riad El-Dada Joins Klotho Neurosciences’ Board of Directors - citybiz
Klotho Neurosciences expands Board with seasoned healthcare executive By Investing.com - Investing.com Canada
Klotho Neurosciences expands Board with seasoned healthcare executive - Investing.com
Klotho Neurosciences, Inc. and Teleost Biopharmaceuticals, LLC Terminate Licensing Agreement - Marketscreener.com
EDIT Stock Drops Amid Market Volatility in Biotech Sector - GuruFocus
Klotho Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Klotho Neurosciences Inc Stock (KLTO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Klotho Neurosciences Inc Stock (KLTO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| CHARDAN CAPITAL MARKETS LLC | 10% Owner |
Jul 01 '24 |
Sale |
2.06 |
115,136 |
237,618 |
1,464,364 |
| CHARDAN CAPITAL MARKETS LLC | 10% Owner |
Jun 28 '24 |
Sale |
2.53 |
47,000 |
119,103 |
1,579,500 |
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):